References

  • European Menopause and Andropause Society (EMAS). Vulvovaginal atrophy. Menopause Essentials; 2022.
  • Hamoda H, Moger S, Morris E, Baldeweg S, Kasliwal A, Gabbay F, et al. Menopause practice standards. Post Reprod Health. 2022;28(3):127-132.
  • Currie H. Vaginal dryness. Women’s Health Concern Factsheet. British Menopause Society; 2023.
  • Briggs P. Genitourinary syndrome of menopause. Post Reprod Health. 2020;26(2):111-114.
  • Briggs P. Consensus statement—urogenital atrophy. Post Reprod Health. 2022;28(1):47-50.
  • Portman DJ, Gass ML. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063-1068.
  • Angelou K, Grigoriadis T, Diakosavvas M, Zacharakis D, Athanasiou S. The genitourinary syndrome of menopause: an overview of the recent data. Cureus. 2020;12(4):e7586.
  • Wysocki S, Kingsberg S, Krychman M. Management of vaginal atrophy: implications from the REVIVE survey. Clin Med Insights Reprod Health. 2014;8:23-30.
  • Hillard T, Abernethy K, Hamoda H, Shaw I, Everett M, Ayres J, et al. Management of the menopause. 6th ed. British Menopause Society; 2017.
  • Parish SJ, Nappi RE, Krychman ML, Kellogg-Spadt S, Simon JA, Goldstein JA, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health. 2013;5:437-447.
  • Palacios S, Nappi RE, Bruyniks N, Particco M, Panay N. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 2018;21(3):286-291.
  • Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790-1799.
  • Nappi RE, Palacios S, Particco M, Panay N. The REVIVE (Real Women’s Views of Treatment Options for Menopausal Vaginal Changes) survey in Europe: country-specific comparisons of postmenopausal women’s perceptions, experiences and needs. Maturitas. 2016;91:81-90.
  • Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric. 2014;17(1):3-9.
  • DiBonaventura M, Luo X, Moffatt M, Bushmakin AG, Kumar M, Bobula J. The association between vulvovaginal atrophy symptoms and quality of life among postmenopausal women in the United States and Western Europe. J Womens Health (Larchmt). 2015;24(9):713-722.
  • Mattsson LA, Cullberg G. A clinical evaluation of treatment with estriol vaginal cream versus suppository in postmenopausal women. Acta Obstet Gynecol Scand. 1983;62:397-401.
  • Genazzani AR, Inaudi P, La Rosa R, et al. Oestriol and the menopause: clinical and endocrinological results of vaginal administration. In Fioretti P, Martini L, Melis GB, Yen SSC. Eds. The menopause: clinical, endocrinological and pathophysiological aspects. Proceedings of the Seronia Symposia, Vol.39. Viarregio May 26-28, 1980. London: Academic Press; 1982. 539‑50.
  • National Institute for Health and Care Excellence (NICE). Menopause: identification and management (NG23). London: NICE; 2024.
  • Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;(8):CD001500.
  • Crandall CJ, Hovey KM, Andrews CA, Chlebowski RT, Stefanick ML, Lane DS, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. 2018;25(1):11-20.
  • Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394:1159-1168.
  • Medicines and Healthcare products Regulatory Agency (MHRA). Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping. Drug Saf Update. 2019 Aug.
  • Vooijs GP, Geurts TB. Review of the endometrial safety during intravaginal treatment with estriol. Eur J Obstet Gynecol Reprod Biol. 1995;62(1):101-106.
  • Nasreen SZA, Shahreen S, Huq S, Huq S. Genito urinary syndrome of menopause (GSM) or vulvo-vaginal atrophy (VVA) an unspoken sorrow. Am J Intern Med. 2019;7(6):154-162.

UK-EST-06-24-00014 June 2026